Celularity Acquires CariCord, Inc., Adds Important Biosourcing Assets, Strategic Relationship with the University of Colorado's ClinImmune Labs
WARREN, N.J., Aug. 31, 2018 /PRNewswire/ -- Celularity, an allogeneic immuno-oncology and placental cell therapeutics company, today announced it entered into a definitive agreement to acquire CariCord, the family cord blood bank established by the University of Colorado and ClinImmune Labs. Through its exclusive ClinImmune Labs relationship, CariCord is the first, and so far the only family cord blood bank to operate inside a FDA Licensed Laboratory. ClinImmune Labs is an academic component of the School of Medicine at the University of Colorado at Denver and Health Sciences Center. Financial details of the transaction were not disclosed.
The acquisition will advance Celularity as an innovation leader through CariCord's strategic relationship with Clinimmune Labs, which operates the University of Colorado Cord Blood Bank (UCCBB), an AABB-accredited, FDA-licensed allogeneic cord blood bank supporting stem cell transplantation worldwide.
"CariCord's national reputation, coupled with ClinImmune's world-class translational research and cell manufacturing capabilities, will add important building blocks in our continued growth and expansion," said Robert J. Hariri, M.D., Ph.D., Celularity's Founder and CEO. "Celularity proprietary technology recovers critical cell populations and tissues from post partum placentas, which is fundamental to our transformative immuno-oncology, cell therapeutics, and functional regeneration applications. Now CariCord, in combination with our legacy business, LifebankUSA, will connect families to many of these same platform technologies, to create their own family bank from their newborn's placenta and cord blood after birth."
"CariCord and Celularity share a vision of a future in which saving the abundant resources in a newborn's placenta after birth is the norm, sparking a sea change in the way we think about longevity and health span," said Calvin Cole, President and CEO of CariCord. "We're immensely excited to become a part of Celularity's transformation of immuno-oncology and cell therapeutics."
The acquisition, which is expected to close during the Fourth Quarter 2018, is subject to regulatory approval and customary closing conditions. Until this is complete, each company will continue to operate independently.
About Celularity, Inc.
Celularity (www.celularity.com), based in Warren, New Jersey, is a biotechnology innovation leader, harnessing the power of placental-derived cell populations to deliver transformative, allogeneic off-the-shelf immunotherapies and cell therapies for cancer and other serious diseases. Visit www.celularity.com to learn more about Celularity.
About CariCord, Inc:
CariCord, Inc., based in Aurora, Colorado, is a leading family cord blood bank established in 2013 by ClinImmune Labs and the University of Colorado. It is associated with the University of Colorado Cord Blood Bank, the United States' second-largest allogeneic cord blood bank. For more information please visit www.CariCord.com.
Legal Notice Regarding Forward-Looking Statements:
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, the asset purchase transaction not being timely completed, if completed at all; prior to the completion of the asset purchase transaction, CariCord's or Celularity's respective businesses experiencing disruptions due to transaction-related uncertainty or other factors making it more difficult to maintain relationships with employees, business partners or governmental entities; and the parties being unable to successfully implement integration strategies or realize the anticipated benefits of the acquisition, including the possibility that the expected synergies and cost reductions from the proposed acquisition will not be realized or will not be realized within the expected time period. We undertake no obligation to publicly update or revise our forward- looking statements as a result of new information, future events or otherwise.